News from wuxi biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 23, 2023, 09:19 ET WuXi Biologics Reports Solid 2023 Interim Results

Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y...

Aug 10, 2023, 20:30 ET WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Boostimmune, a...

Jun 01, 2023, 05:56 ET WuXi Biologics to Increase Manufacturing Capacity in Germany

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that...

Jun 01, 2023, 04:49 ET WuXi Biologics to Increase Manufacturing Capacity in Germany

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that...

May 22, 2023, 04:30 ET WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that ...

May 22, 2023, 04:30 ET WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that ...

May 16, 2023, 04:00 ET WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the...

May 16, 2023, 04:00 ET WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the...

Apr 28, 2023, 02:43 ET WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with...

Mar 28, 2023, 07:05 ET WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its...

Mar 22, 2023, 08:09 ET WuXi Biologics Reports Remarkable 2022 Annual Results

Revenue Increased by 48.4% Y-o-Y to RMB15,268.7 Million Gross Profit Increased by 39.2% Y-o-Y to RMB6,724.0 Million Adjusted Net Profit Rose by 47.1% ...

Mar 08, 2023, 19:30 ET WuXi XDC Congratulates EDDC on FDA Clearance of IND Application for First Made-in-Singapore Antibody-Drug Conjugate

WuXi XDC ("XDC"), a leading global CRDMO company dedicated to end-to-end bioconjugate services, congratulates its partner, the Experimental Drug...

Jan 04, 2023, 19:30 ET WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a...

Dec 15, 2022, 19:44 ET WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its...

Nov 21, 2022, 06:00 ET WuXi Biologics Launches an Integrated Biologics CRDMO Center in Fengxian, Shanghai

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), launched its...

Oct 27, 2022, 10:13 ET WuXi Biologics Provides Corporate Updates

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its...

Oct 26, 2022, 00:30 ET WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China

- The 11th drug substance facility is released for cGMP operation in the WuXi Biologics' global manufacturing network. This new facility enhances the ...

Oct 23, 2022, 20:30 ET WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced its new drug ...

Oct 18, 2022, 21:00 ET WuXi XDC Receives Best CMO Provider Runner Up Prize at 2022 World ADC Awards

WuXi XDC ("XDC"), a leading global CRDMO company dedicated to end-to-end bioconjugates services, announced that it received the Runner Up prize in...

Oct 13, 2022, 21:00 ET WuXi Biologics Receives "Best CDMO Award of the Year"

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has...

Oct 11, 2022, 21:00 ET WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem BioPharma, ...

Oct 11, 2022, 21:00 ET WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem BioPharma, ...

Oct 09, 2022, 20:19 ET WuXi Biologics Co., Ltd. Removed from Unverified List

WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its...

Oct 09, 2022, 19:50 ET WuXi Biologics Co., Ltd. Removed from Unverified List

WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its...

Sep 28, 2022, 22:37 ET WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts

WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO), held a topping-off ceremony,...